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Arene complexesIn an attempt to combine the ability of indolobenzazepines (paullones) to inhibit cyclin-dependent kinases (Cdks)
and that of platinum-groupmetal ions to interact with proteins and DNA, ruthenium(II) and osmium(II) arene com-
plexeswith paulloneswere prepared, expecting synergies and an increase of solubility of paullones. Complexeswith
the general formula [MIICl(η6-p-cymene)L]Cl, whereM=Ru (1, 3) or Os (2, 4), and L=L1 (1, 2) or L2 (3, 4), L1=N-
(9-bromo-7,12-dihydroindolo[3,2-d][1]-benzazepin-6(5H)-yliden-N′-(2-hydroxybenzylidene)azine and L2=N-
(9-bromo-7,12-dihydroindolo[3,2-d][1]benzazepin-6-yl)-N′-[3-hydroxy-5-(hydroxymethyl)-2-methylpyridin-4-yl-
methylene]aziniumchloride (L2*HCl),werenow investigated regarding cytotoxicity andaccumulation in cancer cells,
impact on the cell cycle, capacity of inhibiting DNA synthesis and inducing apoptosis as well as their ability to inhibit
Cdk activity. TheMTT (3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazoliumbromide) assay yielded IC50 values
in the nanomolar to lowmicromolar range. In accordancewith cytotoxicity data, the BrdU assay showed that 1 is the
most and 4 the least effective of these compounds regarding inhibition of DNA synthesis. Effects on the cell cycle are
minor, although concentration-dependent inhibition of Cdk2/cyclin E activity was observed in cell-free experiments.
Inductionof apoptosis ismost pronounced for complex1, accompanied by a low fractionof necrotic cells, as observed
by annexin V–ﬂuorescein isothiocyanate/propidium iodide staining and ﬂow cytometric analysis.
© 2012 Elsevier Inc. Open access under CC BY-NC-ND license.1. Introduction
The search for an alternative to platinum anticancer agents is a
major motivation for continuing investigations concerning the anti-
tumor properties of other transitionmetal-based compounds. Consid-
ering the resistance of many tumors to cisplatin, oxaliplatin or
carboplatin and the adverse effects of these drugs [1,2], great expec-
tations are associated with the antitumor activity and lower general
toxicity of certain ruthenium compounds. Beside ruthenium also os-
mium with similar chemical properties is under investigation, mostly
yielding cytotoxic effects in cancer cell lines comparable to ruthenium
analogues [3]. NAMI-A, a compound aimed at metastasis inhibition,
and KP1019 are examples of promising ruthenium complexes under
clinical investigation [4]. Major advantages of ruthenium are slow li-
gand exchange kinetics, activation by reduction and ability to use
iron transporter mechanisms [5]. Interaction with DNA has been sup-
posed; but given the extensive protein binding of compounds such as
KP1019 [6], protein targets are much more likely to be relevant in: +43 1 4277 9526.
: +43 1 4277 9526.
. Jakupec),
NC-ND license.vivo. Furthermore, ways of cellular accumulation are still being dis-
cussed [7,8].
Indolobenzazepines, also known as paullones, were ﬁrst identiﬁed
as inhibitors of cyclin-dependent kinases (Cdk) by Kunick and co-
workers [9] and are since under investigation regarding not only
their Cdk-inhibition potency but also their effects on glycogen
synthase kinase-3 [8] and mitochondrial malate dehydrogenase
[10]. An underivatized lactam unit and an electron-withdrawing sub-
stituent, such as bromine, favor Cdk-inhibitory activity [11] and have,
at least in some cases, favorable effects on cytotoxicity as well [12].
Insufﬁcient aqueous solubility and bioavailability of paullones have
hampered their further development as anticancer agents. By creat-
ing paullones able to bind to ruthenium(II) and osmium(II) arene
moieties, we expected to reduce the encountered problemsmarkedly.
Moreover, synergistic effects and the differing targets of metals and
ligands could be an advantage for inhibiting cancer cell growth.
Indolobenzazepines with the general formula [MIICl(η6-p-cymene)
L]Cl (L=L1 or L2; M=Ru or Os) (Fig. 1) have been synthesized and
characterized previously [13]. These substances have shown their po-
tency in a cytotoxicity test in three human cancer cell lines, with IC50
values in the lower micromolar range. Hydrolysis behavior and reactiv-
ity to 5′-GMPwere also reported. High cytotoxic activity was the reason
for further studies on their impact on human cancer cells. Because of the
known Cdk-inhibitory activity of themetal-free paullones, inhibition of
Fig. 1. Structures of indolobenzazepine derivatives L1 and L2 and their ruthenium and
osmium arene complexes.
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complexes. Effects on the cell cycle were quantiﬁed by ﬂow cytometry,
and themetal accumulation in the cells, inhibition of DNA synthesis and
induction of apoptosis were compared to cytotoxic potency.2. Experimental section
2.1. Compounds
Compounds 1–4 were prepared as described previously [13]. For
all experiments, the compounds were ﬁrst dissolved in DMSO and
then diluted in medium/buffer as appropriate. Flavopiridol was kind-
ly provided by Sanoﬁ-Aventis.2.2. Cell lines and culture conditions
CH1 (ovarian carcinoma, human) cells were donated by Lloyd R.
Kelland (CRC Centre for Cancer Therapeutics, Institute of Cancer Re-
search, Sutton, U.K.). SW480 (colon adenocarcinoma, human) and
A549 (non-small cell lung cancer, human) cells were kindly provided
by Brigitte Marian (Institute of Cancer Research, Department of Med-
icine I, Medical University of Vienna, Austria). Prostate carcinoma cell
line LNCaP, mammary gland carcinoma cell line T47D as well as the
gastric carcinoma cell line N87 were purchased from the American
Type Culture Collection (ATCC). Cells were grown without antibiotics
in 75-cm2 culture ﬂasks (Iwaki/Asahi Technoglass) as adherent
monolayer cultures in minimal essential medium (MEM) (for CH1,
SW480 and A549 cells) or in RPMI 1640 medium (for LNCaP, N87 and
T47D cells), both media supplemented with 10% heat-inactivated fetal
bovine serum and 4 mM L-glutamine, but only MEM supplemented
with 1 mM sodium pyruvate and 1% non-essential amino acids (from
100× ready-to-use stock) (all purchased from Sigma-Aldrich) without
antibiotics. Cultures were maintained at 37 °C in a humidiﬁed atmo-
sphere containing 5% CO2 and 95% air.2.3. Cytotoxicity in cancer cell lines
Cytotoxicity in the cell lines mentioned above was determined by
the colorimetric MTT assay (MTT=3-(4,5-dimethyl-2-thiazolyl)-2,5-
diphenyl-2H-tetrazolium bromide, purchased from Sigma-Aldrich).
Cells were harvested from culture ﬂasks by trypsinization and seeded
in 100 μL aliquots into 96-well microculture plates (Iwaki/Asahi
Technoglass) in the following densities, in order to ensure exponen-
tial growth of untreated controls throughout the experiment:
1.5×103 (CH1), 2.5×103 (SW480), 4.0×103 (A549), 6.0×103 (N87
and T47D) and 1.0×104 (LNCaP) viable cells per well. Cells were
allowed for 24 h to settle and resume exponential growth in drug-
free MEM, followed by the addition of dilutions of the test compounds
in aliquots of 100 μL/well in the same medium (eventually containing
not more than 0.5% DMSO). After continuous exposure for 96 h, the
medium was replaced by 100 μL/well RPMI 1640 medium plus
20 μL/well solution of MTT in phosphate-buffered saline (5 mg/mL)
(all purchased from Sigma-Aldrich). After incubation for 4 h, medium/
MTT mixtures were removed, and the formazan precipitate formed by
viable cells was dissolved in DMSO (150 μL/well). Optical densities at
550 nm were measured with a microplate reader (Tecan Spectra Clas-
sic), using a reference wavelength of 690 nm to correct for unspeciﬁc
absorption. The quantity of viable cells was expressed as percentage
of untreated controls, and 50% inhibitory concentrations (IC50) were
calculated from concentration–effect curves by interpolation. Evalua-
tion is based on at least three independent experiments, each compris-
ing three replicates per concentration level.
2.4. Kinase assay
The activities of recombinant Cdk2/cyclin E expressed in and isolated
from Sf21 insect cells were determined by a radioassay [14] with minor
modiﬁcations, using histone H1 as the substrate for phosphorylation.
Brieﬂy, MOPS-buffered assay mixtures containing the test compound
(and a maximum of 1% DMSO), the kinase/cyclin complex, histone H1
and 0.4 μCi (γ-32P)ATP per sample were incubated for 10 min at 30 °C.
Aliquots of the solution were spotted onto phosphocellulose squares,
which had been washed 3 times with 0.75% phosphoric acid followed
by acetone. The dried squares were measured in scintillation vials by
beta counting (Perkin Elmer Tri-Carb 2800TR; software: Quanta Smart).
Results were obtained in duplicates in at least two independent
experiments.
2.5. Cell cycle analyses
The impact of the compounds on the cell cycle was studied by ﬂow-
cytometric analysis of DNA contents of cells stainedwith propidium iodide.
Brieﬂy, 1 million A549 cells were seeded into Petri dishes and allowed to
recover for 24 h. Cells were then exposed for 24 h to the test compounds
dissolved in a medium containing a maximum of 0.5% DMSO. Control
and treated cells were collected, washedwith PBS (phosphate-buffered sa-
line), ﬁxed in 70% ice-cold ethanol, and stored at−20 °C. To determine cell
cycle distribution, cells were transferred in physiological saline (0.9% w/v
aqueous NaCl solution) into PBS, incubated with 10 μg/ml RNAse A for
30min at 37 °C, followed by treatment with 5 μg/ml propidium iodide
(PI) for 30min. Fluorescence of 10000 cells was measured with a FACS
Calibur instrument (Becton Dickinson). The resulting DNA histograms
were quantiﬁed by using the Cell Quest Pro software (Becton Dickinson).
2.6. DNA synthesis
Cellular DNA synthesis was quantiﬁed by the BrdU Cell Prolifera-
tion Assay Kit from Millipore. BrdU (5-bromo-2′-deoxyuridine) is in-
corporated into DNA instead of thymidine and serves as an indicator
of DNA synthesis activity of the cells in a colorimetric immunoassay.
For this purpose, 2×105 A549 cells were seeded into 96-well plates
Table 1
Cytotoxicity of ruthenium and osmium arene-based indolobenzazepine complexes in
six human cancer cell lines.
Compound IC50 (μM)
A549 SW480 CH1 LNCaP N87 T47D
1 3.1±0.4 0.64±0.14 0.67±0.11 2.3±0.4 1.1±0.1 0.80±0.10
2 4.6±0.9 1.7±0.1 1.6±0.3 5.3±1.3 1.6±0.3 3.5±0.3
3 6.0±0.3 1.8±0.3 1.5±0.2 5.2±1.5 2.5±0.7 5.8±0.3
4 10±2 4.1±1.0 3.3±0.2 16±1 11±3 12±1
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compounds for 24 h and incubated with BrdU for 6 h afterwards.
For detection by anti-BrdU monoclonal antibody, cells were previous-
ly treated with ﬁxing and denaturizing reagents followed by washing
steps according to the manufacturer's instructions and ﬁnally incu-
bated with a goat anti-mouse IgG peroxidase conjugate. Transforma-
tion of the TMB (3,3′,5,5′-tetramethylbenzidine) substrate was
measured spectrophotometrically at 450/550 nm.
2.7. Cellular accumulation
Studies on cellular accumulation of the compounds were per-
formed according to the method described previously [15]. Brieﬂy,
SW480 cells were seeded in 6-well plates in densities of 3×105
cells per well in aliquots of 2.5 mL complete culture medium. Accu-
mulation experiments and corresponding adsorption/desorption con-
trols were located on the same plate. Plates were kept at 37 °C for
24 h prior to addition of the compounds. Cells were incubated with
the compounds in concentrations of 10 μM for 2 h at 37 °C. After-
wards, the medium was removed, cells were washed three times
with PBS, lysed with 0.5 mL sub-boiled HNO3 per well for 1 h at
room temperature, and ruthenium was quantiﬁed by ICP-MS (induc-
tively coupled plasma mass spectrometry) in aliquots of 400 μL dilut-
ed to a total volume of 8 mL and internally standardized with indium
(0.5 ppb). The adsorption/desorption blank was subtracted from the
corresponding cellular accumulation sample. Results are based on
three independent experiments, each consisting of three replicates.
Metal concentrations were determined by an ICP-MS instru-
ment (Agilent 7500ce, Waldbronn, Germany), equipped with a
CETAC ASX-520 autosampler and a MicroMist nebulizer, at a sample
accumulation rate of approx. 0.25 mL/min. Indium and ruthenium
standards were obtained from CPI International (Amsterdam, The
Netherlands). Standards were prepared in matrices matching the
sample matrix with regard to internal standard and concentration of
the acid. Nitric acid (pro analysi) was purchased from Fluka (Buchs,
Switzerland) and further puriﬁed in a quartz sub-boiling point distil-
lation unit. All samples and dilutions were prepared with Milli-Q
water (18.2 MΩcm). Concentrations were determined by means of
the isotopes 115In and 102Ru.
2.8. Annexin V/propidium iodide assay
This assay was performed in order to determine induction and pro-
gress of apoptosis. This method was described by Aubry et al. [16] and
allows for distinguishing early and late apoptosis as well as necrosis.
In early apoptosis, phosphatidylserine ﬂips from the inner side of the
plasmamembrane to the cell surface, having a Ca2+-dependent afﬁnity
to Annexin V–FITC conjugate which can be measured ﬂuorometrically
at an emission wavelength of 530 nm upon excitation at a wavelength
of 488 nm. Staining with PI, having an emission wavelength of
612 nm upon excitation at 488 nm, on the other hand, requires a loss
of cell membrane integrity and therefore only works in the advanced
apoptotic stage or in necrotic cells.
For this assay, 2×105 SW480 cells per well were seeded into 6-well
plates and allowed to recover for 24 h. Cells were then exposed to dif-
ferent concentrations of test compounds for 48 h. The supernatant
and cells which were detached by trypsinization were transferred into
FACS tubes, centrifuged, and the supernatant was discarded. After
resuspension in 0.5 mL of binding buffer, cells were incubated with
1 μL Annexin V–FITC from Bio Vision. After 5 min, propidium iodide
with an end concentration of 1 μg/mLwas added. Fluorescence was im-
mediatelymeasured byﬂow cytometry using a FACS Calibur instrument
(Becton Dickinson), using FL1 channel for Annexin V-FITC and FL2
channel for PI staining. Resulting dot plots were quantiﬁed by Cell
Quest Pro software (Becton Dickinson).3. Results
3.1. Cytotoxicity in cancer cell lines
Cytotoxicity of the compounds was assessed by means of a color-
imetric microculture assay (MTT assay) in six human cancer cell lines.
The calculated IC50 values are listed in Table 1, and the corresponding
concentration–effect curves are depicted in Fig. 2. Generally, the ovar-
ian cancer cell line CH1 and the colon cancer cell line SW480 are
invariably more sensitive, with IC50 values ranging from 0.67 to
3.3 μM and from 0.64 to 4.1 μM, respectively, whereas the non-small
cell lung cancer cell line A549 and the prostate cancer cell line
LNCaP are less sensitive, with IC50 values ranging from 3.1 to 10 μM
and from 2.3 to 16 μM, respectively. The IC50 values are in all investi-
gated cell lines in the lower micromolar to submicromolar range. The
following structure–activity relationships can be deduced from these
data: ruthenium complexes are in general more active than the osmi-
um analogues. Ruthenium complex 1 (with L1) is in all cell lines at
least 1.5 times (and up to 4.8 times) more active than its osmium an-
alogue 2. The same applies to the complexes with L2, of which ruthe-
nium complex 3 shows at least 1.7 times (and up to 4.4 times) higher
cytotoxicity, depending on the cell line, than the analogous osmium
complex 4. Ruthenium complex 1 is 1.9 to 7.3 times more cytotoxic,
based on a comparison of IC50 values, than complex 3, and osmium
complex 2 is 2.1 to 6.7 times more cytotoxic than 4, indicating that
L1 yields more potent complexes than L2, irrespective of the chosen
metal.
3.2. Inhibition of Cdk activity
Since paullones are known as inhibitors of cyclin-dependent ki-
nases [9], inhibitory potencies of the ruthenium and osmium arene
complexes with L1 and L2were studied in a cell-free setting. In partic-
ular, measurements of kinase activity of recombinant Cdk2/cyclin E
complexes after exposure to 1–4 and to ﬂavopiridol (Fp) as a positive
control were performed by using (γ-32P)ATP and histone H1 as the
substrate for phosphorylation. In general, ruthenium complexes 1
and 3 show a higher inhibitory potency on Cdk2/cyclin E than their
osmium congeners 2 and 4. At a concentration of 10 μM, ruthenium
complexes 1 and 3 yield 43% and 37% inhibition, which is about
twice as high as the effect exerted by osmium congeners 2 and 4. A
50% inhibition of Cdk2/cyclin E requires concentrations of up to
40 μM (or even higher in the case of 2) (Fig. 3). Correlation with cyto-
toxic potencies is rather weak overall, but closest at the intermediate
concentration of 10 μM.
3.3. Cell cycle effects
Given the capacity of inhibiting Cdk activity, an impact on the cell
cycle of proliferating cells might be expected from these compounds.
Therefore, changes in cell cycle distribution induced by 1–4 were
studied in exponentially growing A549 cells treated with these
compounds in varying concentrations for 24 h, then stained with
Fig. 2. Concentration–effect curves of ruthenium (1, 3) and osmium (2, 4) arene-based indolobenzazepine complexes in the human cancer cell lines A549 (A), SW480 (B), CH1 (C),
LNCaP (D), T47D (E) and N87 (F), as obtained by the MTT assay (continuous exposure for 96 h).
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The compounds 1–4 have only weak effects on the cell cycle within the
concentration range tested (Fig. 4). A slight increase of the G0/G1 fraction
and a decrease of the S phase fraction could be observed up to a concen-
tration of 40 μMof complexes 1 and 2. Reduced numbers of cells in G2/M
phase compared to the control are visible at low concentrations of these
compounds (2.5 μM and 10 μM). In the case of complexes 3 and 4, the
cell fraction in G0/G1 phase is slightly increased only at the lowest
(2.5 μM) and/or the medium concentration (10 μM) of the compounds.Fig. 3. Concentration-dependent inhibition of Cdk2/cyclin E activity (means±standard
deviations) by complexes 1–4 in vitro. Flavopiridol (Fp) was used as a positive control.3.4. Incorporation of BrdU
The inhibitory potency of the ruthenium and osmium complexes
on DNA synthesis was determined by the BrdU assay. All four com-
pounds inhibit BrdU incorporation into DNA of A549 non-small cell
lung cancer cells within 24 h. Although the compounds have little ef-
fect on the cell cycle, a clear reduction of DNA synthesis could be ob-
served (Fig. 5). Ruthenium complexes 1 and 3 are again somewhat
more effective than the corresponding osmium complexes 2 and 4,
in accordance with the structure–activity relationships revealed in
the MTT assay. A concentration of 5 μM resulted in nearly 50% and
30% inhibition of BrdU incorporation by 1 and 3, respectively, where-
as the effects of 2 and 4 are still modest. In any case, a strong reduc-
tion of DNA synthesis requires concentrations higher than 5 μM. A
concentration of 20 μM, however, is sufﬁcient for diminishing BrdU
incorporation to values below 15% for all compounds.
3.5. Cellular accumulation
Cellular accumulation of complexes 1 and 3 was studied in the
colon carcinoma cell line SW480. The cells were incubated at 37 °C
for 2 h with 10 μM of the respective compound, and cellular metal
contents were then determined by ICP-MS measurement, revealing
that cellular amounts of ruthenium are one third lower after exposure
to 1 (2.0±0.3 fmol/cell) than those after treatment with 3 (3.0±
0.2 fmol/cell). These results do not correlate with cytotoxicity (com-
pare Fig. 2b). Results obtained with the osmium analogues are not
Fig. 4. Concentration-dependent impact of 1 (A), 2 (B), 3 (C) and 4 (D) on the cell cycle distribution of A549 cells after exposure for 24 h. DNA content of PI-stained cells was an-
alyzed by ﬂow cytometry.
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uncontrolled loss of analyte due to the strongly oxidizing conditions
during cell digestion.
3.6. Induction of apoptosis/necrosis
SW480 colon carcinoma cells were treated with complexes 1–4 for
48 h with concentrations between 5 and 40 μM, and cells were then
collected for annexin V–FITC and propidium iodide staining. Exem-
plarily, dot plots of cell populations treated with 5 μM of eachFig. 5. Impact of complexes 1–4 on DNA synthesis in A549 cells, as determined by the
BrdU incorporation assay after 24 h exposure to the indicated concentrations (μM) of
the compounds.compound from one representative experiment are shown in Fig. 6.
Complex 1 shows the strongest impact on cell viability, only 15%
cells remain viable, whereas cells in early and late apoptosis amount
to 72% in total. Complex 2 shows a much more moderate impact on
cell viability, indicated by 63% viable cells and only 31% apoptotic
cells. The same applies for complex 3, yielding a slightly lower
amount of viable cells (56%) and a slightly higher amount of apoptotic
cells (35%). Complex 4 is the least potent compound and has hardly
any impact on the cells at a concentration of 5 μM. Percentages of ne-
crotic cells remain generally low (with a maximum of 14% in the case
of 1).
The concentration dependence of apoptosis/necrosis induction is
illustrated in Fig. 7, and the corresponding values are listed in
Table 2. They provide further evidence for the differences in cytotoxic
potencies of the compounds, correlating with those observed in the
MTT assay. Whereas 5 μM of compound 1 is sufﬁcient for near-
maximum effect, even 40 μM of compound 4 is insufﬁcient for com-
parable effects. Compounds 2 and 3 require concentrations of 20 μM
to induce 57% and 61% apoptosis, respectively, taking intermediate
positions. Furthermore, compounds 2–4 induce higher proportions
of necrotic cells relative to those undergoing apoptosis, making com-
pound 1 the one with the most favorable properties.
4. Discussion
Binding paullone ligands to ruthenium(II) and osmium(II) arene
moieties led to a considerable improvement of solubility compared
Fig. 6. Flow cytometric quantiﬁcation of apoptotic and necrotic SW480 cells upon exposure to 5 μM of ruthenium and osmium arene complexes with indolobenzazepine ligands
(exposure time 48 h): control (A), 1 (B), 2 (C), 3 (D) and 4 (E). Viable cells appear in the lower left quadrant, necrotic cells in the top left quadrant, early apoptotic cells in the
lower right quadrant and late apoptotic cells in the top right quadrant. (Plots from one representative experiment; numbers inserted indicate the percentages of cells in the respec-
tive quadrant.)
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parison with previous results for Sadler's ruthenium complex with
ethylenediamine (instead of the paullone ligand), [(η6-p-cymene)
RuII(en)Cl](PF6), (IC50 values of 7.1, 3.5 and 4.4 μM in A549, SW480
and CH1 cells, respectively) under the same experimental conditions [17]Fig. 7. Concentration–effect curves of ruthenium and osmium arene-based indolobenzazep
sure, as obtained by ﬂow cytometric quantiﬁcation (means±standard deviations): 1 (A), 2reveals that the presence of the paullone ligand causes a 2.3- to 6.6-fold
(complex 1) and a 1.2- to 2.9-fold (complex 3) increase in cytotoxicity,
depending on the cell line.
In general, complexes with L1 show stronger cytotoxic effects than
those with L2 in all human carcinoma cell lines tested. In the mostine complexes regarding apoptosis/necrosis induction in SW480 cells after 48 h expo-
(B), 3 (C) and 4 (D).
Table 2
Distribution of viable, apoptotic and necrotic SW480 cells (means±standard devia-
tions) after 24 h exposure to ruthenium and osmium arene-based indolobenzazepine




Viable Early apoptosis Late apoptosis Necrosis
Control 0 99±0 b1 b1 b1
1 5 16±2 43±2 28±4 13±4
10 15±2 41±5 28±5 16±5
20 7±1 43±2 35±3 15±2
40 8±3 37±7 38±2 18±2
2 5 62±7 24±6 9±2 5±1
10 31±5 31±8 13±3 24±7
20 13±1 37±4 20±4 30±3
40 8±1 24±3 33±4 34±3
3 5 53±3 23±2 14±2 9±1
10 15±2 32±3 35±2 18±3
20 15±6 43±4 18±2 24±2
40 11±3 23±8 23±3 43±2
4 5 96±2 3±2 1±0 1±1
10 88±2 10±1 1±0 1±1
20 83±2 12±2 3±1 2±1
40 50±6 19±2 13±2 18±3
186 G. Mühlgassner et al. / Journal of Inorganic Biochemistry 116 (2012) 180–187sensitive cell lines SW480 and CH1, IC50 values of complex 1 are in the
nanomolar range, whereas in the least sensitive cell lines A549 and
LNCaP IC50 values are in the low micromolar range.
Whereas differences between ruthenium and osmium analogues
appeared to be rather negligible in a previous report [13], the results
in an extended panel of six cell lines reported here give a clearer indi-
cation that ruthenium is the slightly more favorable central metal
than osmium for cytotoxic activity. As a third-row transition metal
ion, OsII might be expected to be relatively inert compared to the
second-row ion RuII. While fast exchange of the chlorido ligand and
partial loss of the arene ligand was observed for all four complexes,
a different number of cymene and cymene-free paullone species
was detected for ruthenium and osmium complexes, but remarkably
metal-paullone bonds remained intact in water/DMSO mixtures. The
previous observation that the ruthenium complexes form N7 adducts
with 5′-GMP, whereas osmium analogues do not under the same con-
ditions, suggests a higher reactivity of the former to biological target
molecules and may provide an explanation for the different cytotoxic
potencies, which were not so evident in our previous studies [13]. In
this context, covalent DNA binding cannot be excluded as a mode of
action of this type of compounds, similar to simple ruthenium(II)-
arene complexes lacking a biologically active co-ligand [18], but it
seems unlikely that the above-mentioned increased potency mediat-
ed by the presence of a (sterically demanding) paullone ligand (see
ﬁrst paragraph of Discussion) is related to the formation of DNA ad-
ducts. A certain extent of DNA intercalationmight be conceivable (com-
pare the results with a related indolobenzazepine complex [19]), but
the compounds are structurally not particularly predestined for this
kind of interaction, leaving protein interactions as a more likely cause
of the high antiproliferative activities of paullone-based ruthenium(II)
and osmium(II) complexes.
Activity of Cdk2/cyclin E, envisaged as a potential protein target, is
concentration-dependently inhibited by all four compounds, again
strongest by complex 1, which shows at 10 μM about 50% of the in-
hibitory activity of the well-known Cdk inhibitor ﬂavopiridol. Inhibi-
tory potency on Cdk1/cyclin B, which is responsible for the G2/M
transition, was not tested because previous studies with a related os-
mium–paullone complex showed a much lower inhibition of Cdk1/
cyclin B than of Cdk2/cyclin E [19]. Furthermore, the lack of strong
cell cycle effects, in particular the absence of a distinct G2 arrest, ar-
gued against further studies in that direction. Overall, the results
presented here suggest that Cdks are not the crucial target of the
complexes. Probably, the derivatization at the lactam unit of the
paullones is the reason for the decrease in inhibitory potency, inaccordance with the structure–activity relationships described by
Kunick and coworkers [11].
Complex 1 is also most potent in the inhibition of DNA synthesis,
as indicated by reduced BrdU incorporation into newly synthesized
DNA. Overall, the reduction of DNA synthesis, requiring concentra-
tions considerably higher than 5 μM, can hardly be interpreted as a di-
rect interference with processes of the S phase. Rather the lack of a
distinct S phase arrest suggests that the compounds exert their anti-
proliferative effects by inhibiting cell cycle progression more or less
irrespective of the cell cycle phase, thereby also lowering the number
of cells entering the phase of DNA synthesis.
Binding to 5′-GMP in the cell-free setting suggests the possibility
of DNA interactions, at least for the ruthenium complexes, but cannot
explain the cytotoxic potency of the osmium analogues. Moreover,
other ruthenium complexes such as KP1019 are known to avidly
bind proteins, both extra- and intracellular [20], lowering the proba-
bility that DNA interaction is relevant for their antitumor activity in
vivo.5. Conclusion
Cell biological activities of ruthenium/osmium complexes with
modiﬁed paullone (indolobenzazepine) ligands derived from known
Cdk inhibitors were characterized in human cancer cell lines in
vitro. Apart from the beneﬁcial effect on aqueous solubility, the pres-
ence of the paullone ligands seems to be favorable for biological activ-
ity as well. All of these compounds inhibit cancer cell growth in low
micromolar concentrations and induce apoptotic cell death (to a
lower extent also necrosis). The capacity of Cdk inhibition could be
demonstrated in the cell-free setting, but is rather unlikely to be deci-
sive for the antiproliferative activity of the complexes studied here,
given the weak effects on cell cycle progression. Further investiga-








IC50 50% inhibitory concentration
ICP-MS Inductively coupled plasma mass spectrometry
IgG Immunoglobulin G
KP1019 Indazolium trans-[tetrachloridobis(1H-indazole)ruthenate(III)]
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